Literature DB >> 19281769

Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer.

Suzana S Couto1, Mei Cao, Paulo C Duarte, Whitney Banach-Petrosky, Shunyou Wang, Peter Romanienko, Hong Wu, Robert D Cardiff, Cory Abate-Shen, Gerald R Cunha.   

Abstract

Tumor suppressor gene PTEN is important in the initiation and progression of human prostate carcinoma, whereas the role of TP53 remains controversial. Since Pten/Trp53 double conditional knockout mice show earlier onset and fast progression of prostate cancer when compared to Pten knockout mice, we asked whether heterozygosity of these two tumor suppressor genes was sufficient to accelerate prostatic tumorigenesis. To answer this question we examined prostatic lesion progression of Pten/Trp53 double heterozygous mice and a series of controls such as Pten heterozygous, Pten conditional knockout, Trp53 heterozygous and Trp53 knockout mice. Tissue recombination of adult prostatic epithelium coupled with embryonic rat seminal vesicle mesenchyme was used as a tool to stimulate prostatic epithelial proliferation. In our study, high-grade prostatic intraepithelial neoplasia (PIN) was found with high frequency at 8 weeks post-tissue recombination transplantation. PIN lesions in Pten/Trp53 double heterozygous mice were more severe than those seen in Pten heterozygous alone. Furthermore, morphologic features attributable to Pten or Trp53 loss appeared to be enhanced in double heterozygous tissues. LOH analysis of Pten and Trp53 in genomic DNA collected from high-grade PIN lesions in Pten heterozygous and Pten/Trp53 double heterozygous mice showed an intact wild-type allele for both genes in all samples examined. In conclusion, simultaneous heterozygosity of Pten and Trp53 accelerates prostatic tumorigenesis in this mouse model of prostate cancer independently of loss of heterozygosity of either gene.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19281769      PMCID: PMC2828345          DOI: 10.1016/j.diff.2008.09.010

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  53 in total

1.  Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer.

Authors:  Hui Gao; Xuesong Ouyang; Whitney A Banach-Petrosky; William L Gerald; Michael M Shen; Cory Abate-Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

2.  Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation.

Authors:  Shunyou Wang; Alejandro J Garcia; Michelle Wu; Devon A Lawson; Owen N Witte; Hong Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

3.  Promoter analysis of tumor suppressor gene PTEN: identification of minimum promoter region.

Authors:  Xiaoyang Sheng; Dimpy Koul; Juinn-Lin Liu; Ta-Jen Liu; W K Alfred Yung
Journal:  Biochem Biophys Res Commun       Date:  2002-03-29       Impact factor: 3.575

4.  Mesenchymal-epithelial interactions: technical considerations.

Authors:  G R Cunha; A Donjacour
Journal:  Prog Clin Biol Res       Date:  1987

5.  PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway.

Authors:  H Sun; R Lesche; D M Li; J Liliental; H Zhang; J Gao; N Gavrilova; B Mueller; X Liu; H Wu
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

6.  p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.

Authors:  P H Gumerlock; S G Chi; X B Shi; H J Voeller; J W Jacobson; E P Gelmann; R W deVere White
Journal:  J Natl Cancer Inst       Date:  1997-01-01       Impact factor: 13.506

7.  Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis.

Authors:  Minjung J Kim; Robert D Cardiff; Nishita Desai; Whitney A Banach-Petrosky; Ramon Parsons; Michael M Shen; Cory Abate-Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

8.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

9.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

10.  Pten dose dictates cancer progression in the prostate.

Authors:  Lloyd C Trotman; Masaru Niki; Zohar A Dotan; Jason A Koutcher; Antonio Di Cristofano; Andrew Xiao; Alan S Khoo; Pradip Roy-Burman; Norman M Greenberg; Terry Van Dyke; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  PLoS Biol       Date:  2003-10-27       Impact factor: 8.029

View more
  20 in total

1.  eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression.

Authors:  Luc Furic; Liwei Rong; Ola Larsson; Ismaël Hervé Koumakpayi; Kaori Yoshida; Andrea Brueschke; Emmanuel Petroulakis; Nathaniel Robichaud; Michael Pollak; Louis A Gaboury; Pier Paolo Pandolfi; Fred Saad; Nahum Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

2.  Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis.

Authors:  Emily A Ricke; Karin Williams; Yi-Fen Lee; Suzana Couto; Yuzhuo Wang; Simon W Hayward; Gerald R Cunha; William A Ricke
Journal:  Carcinogenesis       Date:  2012-04-25       Impact factor: 4.944

Review 3.  Clinical implications of PTEN loss in prostate cancer.

Authors:  Tamara Jamaspishvili; David M Berman; Ashley E Ross; Howard I Scher; Angelo M De Marzo; Jeremy A Squire; Tamara L Lotan
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

Review 4.  Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Med       Date:  2011-05-20       Impact factor: 6.354

Review 5.  Diverse mechanisms of AKT pathway activation in human malignancy.

Authors:  Mitchell Cheung; Joseph R Testa
Journal:  Curr Cancer Drug Targets       Date:  2013-03       Impact factor: 3.428

Review 6.  Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era.

Authors:  Juan M Arriaga; Cory Abate-Shen
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

Review 7.  Drug discovery in prostate cancer mouse models.

Authors:  Kenneth C Valkenburg; Kenneth J Pienta
Journal:  Expert Opin Drug Discov       Date:  2015-06-01       Impact factor: 6.098

8.  Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.

Authors:  Min Zou; Roxanne Toivanen; Antonina Mitrofanova; Nicolas Floch; Sheida Hayati; Yanping Sun; Clémentine Le Magnen; Daniel Chester; Elahe A Mostaghel; Andrea Califano; Mark A Rubin; Michael M Shen; Cory Abate-Shen
Journal:  Cancer Discov       Date:  2017-04-14       Impact factor: 39.397

9.  Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice.

Authors:  Jehnan Liu; Harrison T Muturi; Saja S Khuder; Raghd Abu Helal; Hilda E Ghadieh; Sadeesh K Ramakrishnan; Meenakshi K Kaw; Sumona Ghosh Lester; Ahmed Al-Khudhair; Philip B Conran; Khew-Voon Chin; Cara Gatto-Weis; Sonia M Najjar
Journal:  Metabolism       Date:  2020-03-21       Impact factor: 8.694

10.  Combined Loss of EAF2 and p53 Induces Prostate Carcinogenesis in Male Mice.

Authors:  Yao Wang; Laura E Pascal; Mingming Zhong; Junkui Ai; Dan Wang; Yifeng Jing; Jan Pilch; Qiong Song; Lora H Rigatti; Lara E Graham; Joel B Nelson; Anil V Parwani; Zhou Wang
Journal:  Endocrinology       Date:  2017-12-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.